Originally published as JCO Early Release 10.1200/JCO.2006.09.4169 on August 6 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blum, W. Articles by Marcucci, G. Search for Related Content PubMed PubMed Citation Articles by Blum, W. Articles by Marcucci, G. Social Bookmarking                            What's this?

Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia

William Blum, Rebecca B. Klisovic, Bjoern Hackanson, Zhongfa Liu, Shujun Liu, Hollie Devine, Tamara Vukosavljevic, Lenguyen Huynh, Gerard Lozanski, Cheryl Kefauver, Christoph Plass, Steven M. Devine, Nyla A. Heerema, Anthony Murgo, Kenneth K. Chan, Michael R. Grever, John C. Byrd, Guido Marcucci

From the Department of Medicine, Division of Hematology and Oncology; Department of Molecular Virology, Immunology, and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University Comprehensive Cancer Center and Solove Research Institute; College of Pharmacy, and Department of Pathology, The Ohio State University, Columbus, OH; Cancer Therapy Evaluation Program, National Institutes of Health, Bethesda, MD; and the Department of Hematology, University of Freiburg Medical Center, Freiburg, Germany

Address reprint requests to William Blum, MD, Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, B310 Starling-Loving Hall, 320 W 10th Ave, Columbus, OH 43210; e-mail: william.blum{at}osumc.edu

Purpose To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML).

Patients and Methods Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML. To determine an OBD (based on a gene re-expression end point), 14 patients received decitabine alone for 10 days. To determine the MTD, 11 patients received decitabine (at OBD, days 1 through 10) plus dose-escalating VA (days 5 through 21).

Results The OBD of decitabine was 20 mg/m²/d intravenously, with limited nonhematologic toxicity. In patients treated with decitabine plus VA, dose-limiting encephalopathy occurred in two of two patients at VA 25 mg/kg/d and one of six patients at VA 20 mg/kg/d. Drug-induced re-expression of estrogen receptor (ER) was associated with clinical response (P .05). ER promoter demethylation, global DNA hypomethylation, depletion of DNA methyltransferase enzyme, and histone hyperacetylation were also observed. In an intent-to-treat analysis, the response rate was 44% (11 of 25). Of 21 assessable patients, 11 (52%) responded: four with morphologic and cytogenetic complete remission (CR; each had complex karyotype), four with incomplete CR, and three with partial remission. In untreated AML, four of nine assessable patients achieved CR. Clinical responses appeared similar for decitabine alone or with VA.

Conclusion Low-dose decitabine was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of decitabine (20 mg/m²/d for 10 days) alone or with an alternative deacetylating agent are warranted.

published online ahead of print at www.jco.org on August 6, 2007.

Supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) Grants No. K23CA120708 (principal investigator, W.B.); NIH/NCI R01 CA102031 (principal investigator, G.M.); NCI U01 CA 76576 (principal investigator, M.R.G.); Leukemia and Lymphoma Society (J.C.B. and C.P.), Dr Mildred Scheel Foundation for Cancer Research postdoctoral Fellowship Grant (B.H.), and D. Warren Brown Foundation (J.C.B.).

Presented in part at American Society of Hematology, Orlando, FL, December 9-12, 2006; and the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 3-6, 2006.

NCI Clinical Trials Network registration: NCT00079378.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. E. Fandy, J. G. Herman, P. Kerns, A. Jiemjit, E. A. Sugar, S.-H. Choi, A. S. Yang, T. Aucott, T. Dauses, R. Odchimar-Reissig, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Blood, September 24, 2009; 114(13): 2764 - 2773. [Abstract] [Full Text] [PDF]

				M. T. Voso, V. Santini, C. Finelli, P. Musto, E. Pogliani, E. Angelucci, G. Fioritoni, G. Alimena, L. Maurillo, A. Cortelezzi, et al. Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes Clin. Cancer Res., August 1, 2009; 15(15): 5002 - 5007. [Abstract] [Full Text] [PDF]

				R. Garzon, S. Liu, M. Fabbri, Z. Liu, C. E.A. Heaphy, E. Callegari, S. Schwind, J. Pang, J. Yu, N. Muthusamy, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 Blood, June 18, 2009; 113(25): 6411 - 6418. [Abstract] [Full Text] [PDF]

				J.-P. J. Issa and H. M. Kantarjian Targeting DNA Methylation Clin. Cancer Res., June 15, 2009; 15(12): 3938 - 3946. [Abstract] [Full Text] [PDF]

				H. M. Prince, M. J. Bishton, and S. J. Harrison Clinical Studies of Histone Deacetylase Inhibitors Clin. Cancer Res., June 15, 2009; 15(12): 3958 - 3969. [Abstract] [Full Text] [PDF]

				M. Bots and R. W. Johnstone Rational Combinations Using HDAC Inhibitors Clin. Cancer Res., June 15, 2009; 15(12): 3970 - 3977. [Abstract] [Full Text] [PDF]

				K. A. Blum, Z. Liu, D. M. Lucas, R. Baiocchi, T. S. Lin, D. Benson, S. M. Devine, J. Jones, L. Andritsos, J. Flynn, et al. A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 3169 - 3169. [Abstract]

				O. M. Odenike, S. Alkan, D. Sher, J. E. Godwin, D. Huo, S. J. Brandt, M. Green, J. Xie, Y. Zhang, D. H. Vesole, et al. Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia Clin. Cancer Res., November 1, 2008; 14(21): 7095 - 7101. [Abstract] [Full Text] [PDF]

				B. Hackanson, H. Becker, T. Berg, M. Binder, C. Dierks, J. Duque-Afonso, M. D. Lairmore, H. S. Schafer, M. Schnitzler, R. Zeiser, et al. XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from Molecular Pathogenesis to Targeted Therapy in Leukemia and Solid Tumors Cancer Res., July 15, 2008; 68(14): 5512 - 5518. [Full Text] [PDF]

				B. Hackanson, K. L. Bennett, R. M. Brena, J. Jiang, R. Claus, S.-S. Chen, N. Blagitko-Dorfs, K. Maharry, S. P. Whitman, T. D. Schmittgen, et al. Epigenetic Modification of CCAAT/Enhancer Binding Protein {alpha} Expression in Acute Myeloid Leukemia Cancer Res., May 1, 2008; 68(9): 3142 - 3151. [Abstract] [Full Text] [PDF]

				T. Haferlach Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia Hematology, January 1, 2008; 2008(1): 400 - 411. [Abstract] [Full Text] [PDF]